FDA approves Teva's Weltruza as first once-monthly subcutaneous LAI for schizophrenia

The US FDA has approved Teva's Weltruza as the first once-monthly subcutaneous long-acting injectable for schizophrenia, eliminating the need for loading doses, oral supplementation, or post-injection monitoring.

This Wire brief sits within Fusion42's coverage of Medtech, and 20 sources have reported it between 9 Oct 2026 and 13 Oct 2026.